Table 2 Admission and discharge metrics
Azithromycin (N = 5,102) | Cortico-steroids (N = 8,498) | Hydroxy-chloroquine (N = 1,239) | Remdesivir (N = 4,124) | Tocilizumab (N = 800) | Total (N = 9,638) | |
|---|---|---|---|---|---|---|
Admission Source | ||||||
Direct Admit from Home | 4,516 (88.51%) | 7,233 (85.11%) | 1,063 (85.79%) | 3,587 (86.98%) | 714 (89.25%) | 8,209 (85.17%) |
Interfacility Transfer | 586 (11.49%) | 1,265 (14.89%) | 176 (14.21%) | 537 (13.02%) | 86 (10.75%) | 1,429 (14.83%) |
Admission Quarter (2020) | ||||||
Q1 | 365 (7.15%) | 180 (2.12%) | 375 (30.27%) | 14 (0.34%) | 19 (2.38%) | 451 (4.68%) |
Q2 | 1,698 (33.28%) | 2,102 (24.74%) | 782 (63.12%) | 820 (19.88%) | 530 (66.25%) | 2,770 (28.74%) |
Q3 | 1,555 (30.48%) | 3,035 (35.71%) | 60 (4.84%) | 1,442 (34.97%) | 232 (29.00%) | 3,142 (32.60%) |
Q4 | 1,484 (29.09%) | 3,181 (37.43%) | 22 (1.78%) | 1,848 (44.81%) | 19 (2.38%) | 3,275 (33.98%) |
Discharge Disposition | ||||||
Expired | 1,967 (38.55%) | 3,824 (45.00%) | 543 (43.83%) | 1,665 (40.37%) | 433 (54.13%) | 4,193 (43.50%) |
Home | 2,347 (46.00%) | 3,329 (39.17%) | 487 (39.31%) | 1,834 (44.47%) | 271 (33.88%) | 3,907 (40.54%) |
Transfer Out | 170 (3.33%) | 229 (2.69%) | 46 (3.71%) | 125 (3.03%) | 30 (3.75%) | 279 (2.89%) |
Inpatient Rehab | 618 (12.11%) | 1,116 (13.13%) | 163 (13.16%) | 500 (12.12%) | 66 (8.25%) | 1,259 (13.06%) |